BR9808016A - Composições e métodos para redução da hipertensão ocular - Google Patents

Composições e métodos para redução da hipertensão ocular

Info

Publication number
BR9808016A
BR9808016A BR9808016-4A BR9808016A BR9808016A BR 9808016 A BR9808016 A BR 9808016A BR 9808016 A BR9808016 A BR 9808016A BR 9808016 A BR9808016 A BR 9808016A
Authority
BR
Brazil
Prior art keywords
compositions
prostaglandin
methods
ocular hypertension
reducing
Prior art date
Application number
BR9808016-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Kenneth Warren Reed
Shau-Fong Yen
Mary Sou
Regina Flinn Peacock
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9808016(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to BRPI9816218A priority Critical patent/BRPI9816218B1/pt
Publication of BR9808016A publication Critical patent/BR9808016A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9808016-4A 1997-03-17 1998-03-13 Composições e métodos para redução da hipertensão ocular BR9808016A (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI9816218A BRPI9816218B1 (pt) 1997-03-17 1998-03-13 "composições para redução da hipertensão ocular, e seu uso na preparação de composições oftálmicas"

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17
PCT/EP1998/001483 WO1998041208A1 (en) 1997-03-17 1998-03-13 Compositions and methods for reducing ocular hypertension

Publications (1)

Publication Number Publication Date
BR9808016A true BR9808016A (pt) 2000-03-08

Family

ID=38729083

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9808016-4A BR9808016A (pt) 1997-03-17 1998-03-13 Composições e métodos para redução da hipertensão ocular
BRPI9816218A BRPI9816218B1 (pt) 1997-03-17 1998-03-13 "composições para redução da hipertensão ocular, e seu uso na preparação de composições oftálmicas"

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9816218A BRPI9816218B1 (pt) 1997-03-17 1998-03-13 "composições para redução da hipertensão ocular, e seu uso na preparação de composições oftálmicas"

Country Status (32)

Country Link
EP (1) EP0969846B2 (https=)
JP (2) JP4920124B2 (https=)
KR (1) KR100555818B1 (https=)
CN (1) CN1236775C (https=)
AR (2) AR002194A1 (https=)
AT (1) ATE257385T1 (https=)
AU (1) AU738781B2 (https=)
BR (2) BR9808016A (https=)
CA (1) CA2280089C (https=)
CL (1) CL2009001870A1 (https=)
CO (1) CO4940427A1 (https=)
CY (1) CY2526B1 (https=)
CZ (1) CZ299833B6 (https=)
DE (1) DE69820997T3 (https=)
DK (1) DK0969846T4 (https=)
EE (1) EE04091B1 (https=)
ES (1) ES2214706T5 (https=)
HU (1) HU228896B1 (https=)
ID (1) ID22389A (https=)
IL (1) IL131041A0 (https=)
MY (1) MY122237A (https=)
NO (1) NO327713B1 (https=)
NZ (1) NZ337322A (https=)
PE (1) PE61899A1 (https=)
PL (1) PL197509B1 (https=)
PT (1) PT969846E (https=)
RU (1) RU2197970C2 (https=)
SI (1) SI0969846T2 (https=)
TW (1) TW527187B (https=)
UA (1) UA63938C2 (https=)
WO (1) WO1998041208A1 (https=)
ZA (1) ZA982188B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
CA2422031C (en) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
AU2002218527A1 (en) * 2000-12-05 2002-06-18 Sankyo Company Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
WO2005089755A1 (en) * 2004-03-18 2005-09-29 R-Tech Ueno, Ltd. Aqueous composition comprising thiazole derivative
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
EP1916002B1 (en) * 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
CN101400354B (zh) * 2006-03-13 2014-10-22 株式会社·R-技术上野 水性组合物
KR101454674B1 (ko) * 2006-03-17 2014-10-27 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물
RU2465898C2 (ru) * 2006-10-31 2012-11-10 Алькон Рисерч, Лтд. Модуляторы связывания pai-1 для лечения глазных болезней
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
NZ584275A (en) * 2007-10-08 2012-06-29 Fovea Pharmaceuticals Aqueous cyclosporine ophthalmic formulations
ES2638771T3 (es) * 2008-03-17 2017-10-24 Novartis Ag Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
CA2858574C (en) 2011-12-07 2017-05-30 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
NZ732058A (en) 2014-11-25 2023-06-30 Allergan Inc Stabilized omega-3 ophthalmic compositions
AU2019343188A1 (en) * 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
AU2020272127B2 (en) 2019-04-12 2022-12-08 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69100171T2 (de) * 1990-05-22 1993-10-28 Ueno Seiyaku Oyo Kenkyujo Kk Synergistische Kombination zur ophthalmischen Verwendung.
WO1992013836A1 (en) * 1991-02-07 1992-08-20 Allergan, Inc. 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
EP0708646A1 (en) * 1994-05-06 1996-05-01 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
CA2280089C (en) 2009-03-03
HUP0002194A2 (hu) 2000-12-28
CN1249687A (zh) 2000-04-05
PE61899A1 (es) 1999-06-30
EP0969846B2 (en) 2010-08-25
DE69820997D1 (de) 2004-02-12
TW527187B (en) 2003-04-11
HK1026841A1 (en) 2000-12-29
JP2010043110A (ja) 2010-02-25
DE69820997T3 (de) 2011-10-06
NZ337322A (en) 2001-05-25
ATE257385T1 (de) 2004-01-15
SI0969846T2 (sl) 2010-12-31
CA2280089A1 (en) 1998-09-24
JP4920124B2 (ja) 2012-04-18
SI0969846T1 (en) 2004-06-30
PL197509B1 (pl) 2008-04-30
DE69820997T2 (de) 2004-12-09
KR20000076330A (ko) 2000-12-26
EE04091B1 (et) 2003-08-15
EP0969846A1 (en) 2000-01-12
UA63938C2 (uk) 2004-02-16
CZ299833B6 (cs) 2008-12-10
AR011192A1 (es) 2000-08-02
AR002194A1 (es) 1998-01-07
CY2526B1 (en) 2006-02-08
NO994481L (no) 1999-09-16
ID22389A (id) 1999-10-07
WO1998041208A1 (en) 1998-09-24
AU738781B2 (en) 2001-09-27
NO994481D0 (no) 1999-09-16
KR100555818B1 (ko) 2006-03-03
ES2214706T3 (es) 2004-09-16
MY122237A (en) 2006-04-29
JP2001515502A (ja) 2001-09-18
DK0969846T4 (da) 2010-12-20
BRPI9816218B1 (pt) 2016-04-12
AU7035398A (en) 1998-10-12
CZ325799A3 (cs) 2000-01-12
HUP0002194A3 (en) 2012-08-28
ES2214706T5 (es) 2011-02-02
PT969846E (pt) 2004-05-31
NO327713B1 (no) 2009-09-14
RU2197970C2 (ru) 2003-02-10
CO4940427A1 (es) 2000-07-24
CN1236775C (zh) 2006-01-18
ZA982188B (en) 1998-09-17
EP0969846B1 (en) 2004-01-07
IL131041A0 (en) 2001-01-28
CL2009001870A1 (es) 2010-01-22
HU228896B1 (en) 2013-06-28
PL335168A1 (en) 2000-04-10
DK0969846T3 (da) 2004-04-13
EE9900410A (et) 2000-04-17

Similar Documents

Publication Publication Date Title
BR9808016A (pt) Composições e métodos para redução da hipertensão ocular
MX9405006A (es) Solucion oftalmica para lagrimas artificiales.
IT1277707B1 (it) Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
PT868186E (pt) Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
ES2178263T3 (es) Composiciones oftarmologicas que contienen un glicosido cationico y unagente terapeutico anionico.
KR101820184B1 (ko) 방부제가 없는 비마토프로스트 및 티몰롤 용액
PL1937212T3 (pl) Emulsje oftalmiczne zawierające prostaglandyny
NO975962D0 (no) Legemiddelpreparat som omfatter albumin som aktiv bestanddel
WO2002049615A3 (en) Artificial tear composition containing a combination of three demulcents
EP1007028A1 (en) 8-iso-prostaglandins for glaucoma therapy
ES2183148T3 (es) Composiciones oftalmicas que contienen un inhibidor de anhidrasa carbonica y de la goma de xantano.
WO2002049611A3 (en) Ophthalmic lubricating solution adapted for use in lasik surgery
JP2001187733A5 (https=)
AU609807B2 (en) A composition for the topical treatment of glaucoma or ocular hypertension
JP3175742B1 (ja) コンタクトレンズ用眼科用組成物
ITRM20010438A1 (it) Preparato oftalmico a base di n-acetilcisteina per il trattamento della sindrome dell'occhio secco.
EP0979652A4 (en) CURATIVE COMPOSITION OF INTRAOCULAR HYPERTENSION OR GLAUCOMA
BR0209601A (pt) Método para o tratamento da hipertensão ocular e do glaucoma
PT1021184E (pt) Utilizacao de flunarizina para o tratamento topico da hipertensao ocular
MXPA04000980A (es) Tratamiento de hipertension ocular y glaucoma.
ES2106852T3 (es) Composicion oftalmica que contiene hemihidrato de timolol.
ATE227135T1 (de) Miotische wirkstoffe und hypertonische wirkstoffe enthaltende ophthalmische zusammensetzungen
JP4736540B2 (ja) 眼科用粘稠化剤
JP2011084575A (ja) 点眼液
ECSP982443A (es) Composiciones y metodos para reducir la hipertension ocular

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO DISPOSTO NOS ARTIGOS 8O, 11 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 31/557, A61K 9/00, AO1B 1/00

Ipc: A61K 31/557 (2010.01), A61K 9/00 (2010.01), A61P 2